1Antman EM,McCabe CH,Gurfinkel E,et al.Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction.Results of thrombolysis in myocardial infarction 11B trial.Circulation,1999,100:1593-1601.
2Cohen M,Demers C,Gurfinkel EP,et al.The efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group.A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease.N Engl J Med,1997,337:447-452.
3Mahaffey KW,Ferguson JJ.Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes:The synergy trial.Am Heart J,2005,149:S81-90.
4Choussat R,Montalescot G,Collet JP,et al.A unique low dose of intravenous enoxaparin in elective percutaneous coronary intervention.J Am Coll Cardiol,2002,40:1943-1950.
6Kereiakes DJ,Montalescot G,Antman EM,et al.Lowmolecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention:an expert consensus.Am Heart J,2002,144:615-624.
7Montalescot G,Collet JP,Tanguy ML,et al.Anti-Ⅹa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.Circulation,2004,110:392-398.
8Moliterno DJ,Hermiller JB,Kereiakes DJ,et al.A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention:results of the evaluating enoxaparin clotting times study.J Am Coll Cardiol,2003,42:1132-1139.
9The thrombolysis in myocardial infarction 11A trial investigators.Dose-ranging trial of enoxaparin for unstable angina:Results of TIMI 11A.J Am Coll Cardiol,1997,29:1474-1482.
10Collet JP,Montalescot G,Lison L,et al.Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.Circulation,2001,103:658-663.
2Antman EM death and cardiac ischemic events in unstable angina/non - Q - wavemyocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI)11B trial [ J ]. Circulation, 1999,100 : 1593 - 1601.
3Serebruany VL tenecteplase versus alteplase on platelets during the first 3 hours oftreatment for acute myocardial infarction:the Assessment of the Safety and Efficacy of a New Thrombolytic Agent ( ASSENT - 2) platelet substudy [ J ]. Am Heart J ,2003,145:636 - 642;
4Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low - molecular- weight heparin enoxaparin or unfractionated heparin in the prehospital setting:the Assessment of the Salety and Efficacy of a New Thrombolytic Regimen( AS- SENT) -3 PLUS randomized trial in acute myocardial infarction [ J ]. Circulation,2003,108 : 135 - 142.
5Sanchez - Pena P, Hulot JS, Urinen S, et al. Anti - faetor Xa kinetics after intravenous enoxaparin in patients under-going percutaneous coronary intervention: a population model analysis [ J ]. Br Clin Pharmacol, 2005,60 : 364- 373.
6ntalescol G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute corenary syndrome patients treated with enoxaparin[ J ]. Circulation,2004,110 : 392 - 398.
